Skip to main content

Table 2 Relationship of the tertile of serum sRAGE with the prevalence of MetS in men (n = 712) a

From: Higher serum soluble receptor for advanced glycation end product levels and lower prevalence of metabolic syndrome among Japanese adult men: a cross-sectional study

 

Tertiles of serum sRAGE

 

Median, interquartile range (pg/mL)

Low (n = 238)

Middle (n =237)

High (n =237)

P for trendb

 

(847.6, 710.0–950.0)

(1259.1, 1152.8–1377.2)

(1835.0, 1608.9–2107.8)

 

MetS

    

 Crude

1.00

0.85 (0.57–1.27)

0.47 (0.31–0.73)

<0.001

 Model 1c

1.00

0.89 (0.59–1.35)

0.45 (0.28–0.71)

0.001

 Model 2d

1.00

1.04 (0.67–1.61)

0.58 (0.36–0.95)

0.038

Central obesity

    

 Crude

1.00

0.88 (0.60–1.29)

0.37 (0.24–0.57)

<0.001

 Model 1c

1.00

0.86 (0.58–1.27)

0.33 (0.21–0.52)

<0.001

 Model 2d

1.00

0.96 (0.64–1.45)

0.41 (0.25–0.66)

<0.001

 Model 3e

1.00

0.99 (0.65–1.52)

0.46 (0.28–0.75)

0.003

Elevated BP

    

 Crude

1.00

0.55 (0.38–0.80)

0.33 (0.22–0.48)

<0.001

 Model 1c

1.00

0.61 (0.40–0.93)

0.38 (0.25–0.57)

<0.001

 Model 2d

1.00

0.66 (0.43–1.02)

0.45 (0.29–0.70)

<0.001

 Model 3e

1.00

0.65 (0.42–1.01)

0.49 (0.31–0.77)

0.002

Elevated FBG

    

 Crude

1.00

1.01 (0.69–1.48)

0.70 (0.47–1.04)

0.078

 Model 1c

1.00

1.17 (0.78–1.75)

0.89 (0.58–1.37)

0.64

 Model 2d

1.00

1.21 (0.81–1.84)

0.97 (0.63–1.51)

0.95

 Model 3e

1.00

1.29 (0.85–1.96)

1.20 (0.76–1.89)

0.40

Elevated TG

    

 Crude

1.00

1.01 (0.69–1.47)

0.68 (0.46–1.03)

0.054

 Model 1c

1.00

1.00 (0.68–1.48)

0.62 (0.41–0.93)

0.024

 Model 2d

1.00

1.11 (0.74–1.65)

0.75 (0.49–1.65)

0.19

 Model 3e

1.00

1.17 (0.77–1.77)

0.85 (0.54–1.33)

0.50

Reduced HDL-C

    

 Crude

1.00

0.91 (0.54–1.52)

0.94 (0.56–1.57)

0.81

 Model 1c

1.00

0.77 (0.44–1.33)

0.63 (0.36–1.11)

0.11

 Model 2d

1.00

0.88 (0.45–1.56)

0.87 (0.46–1.56)

0.65

 Model 3e

1.00

0.85 (0.47–1.53)

0.90 (0.48–1.68)

0.74

  1. aData are odds (95% confidence interval). sRAGE, soluble receptor of advanced glycation end-products; MetS, metabolic syndrome.
  2. bMultiple logistic regression analysis.
  3. cAdjusted for age (continuous variable), smoking status (never, former, or current), drinking status (never, ≤ 3 day(s)/week, 4–6 days/week, or every day), educational level (≥college or not), occupation (desk work or non-desk work), depressive symptoms (Self-Rating Depression Scale ≥40 or not), physical activity (<1.0 METs · hour/week, 1.0–22.9 METs · hour/week, or ≥23.0 METs · hour/week), total energy intake (continuous variable), sleep time (≥6 and ≤8 hours/day or not), and eGFR (continuous variable).
  4. dAdditionally adjusted for serum high sensitivity C-reactive protein concentration (continuous variable).
  5. eAdditionally adjusted for mutual metabolic syndrome components.